# Efficacy and Safety of Oral Dehydroepiandrosterone as a Concomitant Therapy to Oral Contraceptives in Women Complaining of Reduced Libido

> **NCT00566384** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 100 (actual)

## Conditions studied

- Libido

## Interventions

- **DRUG:** Dehydroepiandrosterone, BAY86-5314
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00566384
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2014-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00566384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00566384, "Efficacy and Safety of Oral Dehydroepiandrosterone as a Concomitant Therapy to Oral Contraceptives in Women Complaining of Reduced Libido". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00566384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*